Navigation Links
In just 5 years, gene discovery to clinical trial of potential treatment
Date:12/14/2008

One of the fastest translations of a basic research discovery into a promising clinical trial for an "untreatable" and fatal disorder will be discussed publicly for the first time by the key players in this remarkable research story, on Sunday, Dec. 14, at the American Society for Cell Biology (ASCB)'s annual meeting in San Francisco.

The disease is Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), a rare, accelerated aging disease that afflicts children.

The discovery of the gene responsible for the disease five years ago led scientists to the experimental drug that is now being evaluated in 28 children with this "premature aging" disease.

Speaking at the special ASCB session will be the physician heading the clinical trial, the gene-hunter whose research team pinpointed the DNA mutation, and the cell biologist who conducted the basic research on the protein structures in the cell nucleus that were subsequently found to be abnormal in HGPS.

Also on the panel will be the medical director of the Progeria Research Foundation who is both a scientist and the mother of a child with HGPS.

In addition to describing this bench-to-bedside story, the ASCB special symposium will spotlight new research suggesting that the basic cellular mechanism defective in children with HGPS may be at work in "normal" aging disorders, particularly in cardiovascular disease.

HGPS is estimated to affect about one child in 4 million. At birth, children with the disease appear normal. However, their growth soon slows, and children with HGPS begin to show signs of accelerated aging, such as hair loss, wrinkled skin, and loss of body fat. A 10-year-old child with HGPS typically looks like an 80-year-old adult.

HGPS' lethal damage occurs within the major blood vessels. The children develop premature cardiovascular disease, which typically leads to death from heart attack or stroke at about the age of 13. There currently
'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
American Society for Cell Biology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Discovery may help defang viruses
2. Stomach stem cell discovery could bring cancer insights
3. Symposium marks 30th anniversary of discovery of third domain of life
4. Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia
5. Natural product discovery by Cleveland medical researchers blocks tissue destruction
6. Researchers discovery may lead to hypertension treatment
7. Yale discovery suggests protein may play a role in severe asthma
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. Profound immune system discovery opens door to halting destruction of lupus
10. Scripps Research discovery leads to broad potential applications in CovX-Pfizer deal
11. New discovery could reduce the health risk of high-fat foods

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...University Medical Center researchers have figured...glioma may be better able to resist radiation ther...ing pathway in these cancer stem cells, they were ... in a laboratory experiment. , The work builds ... cells resist the effects of radiation much better...
(Date:12/2/2009)...e smokeless tobacco product called moist snuff pl...nnesota to urge the tobacco industry to change man...carcinogens. Their study is published online in AC...y . It reports that this category of tobacco produ...oxic and cancer-causing substances. Called polycyc...
(Date:12/2/2009)...r muscles can twitch, before the thought telling i...te of sortscalled an ion channelmust open in the s...chemical signals that spur the cell to action. New...and Technology (NIST) has allowed scientists to ob... the first time, potentially offering insights for...
Breaking Biology News(10 mins):Discovery makes brain tumor cells more responsive to radiation 2Nervy research: Researchers take initial look at ion channels in a model system 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 1Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 1Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 1Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 2Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 3Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 4Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 5Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 6Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 8Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 9Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 10Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 11Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 12Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 13Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 14Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 15Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 16Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 17Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 18
...pidly distributing antibiotics to people,exposed t...ld by,itself, prevent about 70 percent of anthrax ...s from the Johns Hopkins Bloomberg School of,Publi...rcent, their,study found that at least 63 percent ...vaccine before an anthrax attack, which might not ...
... Southwestern Medical Center at Dallas,researchers...s of mice,to fight against amyloid proteins that c...ic of Alzheimer,s disease.,For years scientists ha...ed vaccine to slow the progression of the disease ...ave created a gene-based,vaccine aimed at stimulat...
...ientists have believed that neurons need a long pe...s before they take on their adult role. But after ...hese cells develop, a team of researchers at the S...eurons come into this world with a good idea about...is detailed in a paper in the March 24 issue of Ne...
Other Biology News:Study Models Impact Of Anthrax Vaccine 2Scientists identify molecular events that drive cell senescence 2First real-time view of developing neurons reveals surprises, say Stanford researchers 2
(Date:12/3/2009)..., , PHILADELPHIA, Dec. 3 /PRNewswire-FirstC... global specialty biopharmaceutical company, today...untary market withdrawal of one lot of the Attenti...trana ® . Shire is taking this action because...e may not meet their release liner removal specifi...
(Date:12/2/2009)..., , COLUMBIA, Md., Dec. 2 /PRNewswire-Firs... MATK ) announced today that it intends to release... 2009 on December 16, 2009, at approximately 4:00 ... 4:45 p.m. ET Martek will conduct a conference cal...terested parties may listen to the call live via w...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire-USNewswire...tists, policy makers, and funders today convened t...ive funding strategies at the inaugural Partnerin...shington-based center of the Milken Institute, con...ector collaborations needed to turn a scientific d...
(Date:12/2/2009)..., , LELYSTAD, The Netherlands, December...ands based biotechnology company focusing on prote...ne therapeutics today announced that it,has appoin...icer. , Dr. Mol will be responsible for a... management and strategic direction of the company...
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Dutch Biotech Company Pepscan Appoints New CEO 2
... Celator Pharmaceuticals today,announced that Scot...o,present at the BIO Investor Forum in San Francis...and an update on the company,s clinical,developmen...sday, October,29, 2008 at 1:45 PM PDT in the Marin...pleased to announce that Dr. Arthur Louie, chief,m...
...Alfacell Corporation,(Nasdaq: ACEL ) today announ...scal year ended July 31, 2008, filed with the Secu...ncluded an audit opinion from its independent,regi... about the company,s,ability to continue as a goin...compliance with NASDAQ Marketplace Rule 4350(b)(1)...
...pril 27, 2009 to Regain Compliance with $1.00 ...IN, Calif., Oct. 23 Peregrine,Pharmaceuticals, In...tical,company developing monoclonal antibodies for...ons, today announced that it has received a letter...al time to regain,compliance with the minimum bid ...
Other Biology Technology:Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum 2Alfacell Receives Going Concern Audit Opinion 2Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule 2
Rabbit Anti-Phospho RNA Polymerase II (S5) Polyclonal Antibody, Unconjugated from Bethyl Laboratories
...pitant to ensure that the samples sink into the we... the progress of electrophoresis. Components R...e of red dye and precipitant with the same buffer...ht markers. It is the same dye used in our ReddyMi...
Human Exodus-2 from MBL International
Corning Flask, 225cm2, Angled Neck, Vent Cap from Sigma-Aldrich
Biology Products: